Diligence memo · auto-generated · as of July 3, 2026
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Treeline Biosciences, Inc. operates in Biotechnology, based in WATERTOWN. Treeline
Capital & rounds (filed)filed
Treeline Biosciences, Inc. has raised $1.1B in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $422M on 2024-10-02.
Most recent recorded round closed around 2025-08-21.
Valuation (modeled)modeled
Provath models Treeline Biosciences, Inc. at approximately $1.9B (range $1.2B–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.65× the median modeled value of Growth/Late Biotechnology companies in 2025–2027 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 10 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 2.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Neuralink Corp., Eikon Therapeutics, Inc., Grail, Inc., Castle Creek Biosciences, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.